Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Redwood Investments LLC

Redwood Investments LLC trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 71.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 93,050 shares of the biopharmaceutical company's stock after selling 235,409 shares during the period. Redwood Investments LLC owned approximately 0.07% of Halozyme Therapeutics worth $3,439,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Assenagon Asset Management S.A. lifted its holdings in shares of Halozyme Therapeutics by 76.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 125,207 shares of the biopharmaceutical company's stock valued at $4,628,000 after purchasing an additional 54,063 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Halozyme Therapeutics by 137.3% during the fourth quarter. Pacer Advisors Inc. now owns 26,376 shares of the biopharmaceutical company's stock valued at $975,000 after acquiring an additional 15,261 shares in the last quarter. FCF Advisors LLC increased its position in shares of Halozyme Therapeutics by 431.4% during the fourth quarter. FCF Advisors LLC now owns 20,773 shares of the biopharmaceutical company's stock valued at $768,000 after acquiring an additional 16,864 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of Halozyme Therapeutics by 89.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 46,121 shares of the biopharmaceutical company's stock valued at $1,762,000 after acquiring an additional 21,747 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Halozyme Therapeutics by 22.8% during the third quarter. Wellington Management Group LLP now owns 155,731 shares of the biopharmaceutical company's stock valued at $5,949,000 after acquiring an additional 28,958 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.64 during mid-day trading on Monday, reaching $41.32. 801,003 shares of the company's stock traded hands, compared to its average volume of 1,340,104. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $45.00. The firm has a 50 day moving average price of $38.22 and a two-hundred day moving average price of $37.72. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The firm has a market capitalization of $5.25 billion, a PE ratio of 19.58, a price-to-earnings-growth ratio of 0.49 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The business had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 3.33 EPS for the current year.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the transaction, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,519,075.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HALO shares. TheStreet downgraded shares of Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research report on Monday, January 22nd. JMP Securities reissued a "market outperform" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. The Goldman Sachs Group cut their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating for the company in a research report on Thursday, January 18th. StockNews.com raised shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, February 23rd. Finally, Benchmark reaffirmed a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Friday, January 19th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.